Ahmed Aly Elghawy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmed Aly Elghawy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Bag-Ozbek
Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, SUNY Stonybrook University Hospital, Stonybrook, NY 11794, USA
2 shared publications - Maria Skopis
Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
2 shared publications - Adam Jacobs
Mount Sinai Medical Center, Miami Beach, FL, United States
1 shared publication - Barbara Pociurko
Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, USA
1 shared publication Carlos Sesin
Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA
1 shared publication- Diego Lugo Baruqui
Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA
1 shared publication
Latest Publications
- Open Access
- 3 August 2023
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 19 (4) , 400-407
Current State of Platelet-rich Plasma in the Treatment of Rheumatic Disease: A Retrospective Review of the Literature
Introduction: Rheumatic diseases are a spectrum of autoimmune or inflammatory diseases that cause damage to the musculoskeletal system as well as vital organs, such as the heart, lungs, kidneys, and central nervous system. Methods: The study of rheumatic disease has made great pro-gress in the understanding and management of these conditions in the last few decades using dis-ease-modifying antirheumatic drugs and synthesized biological immunomodulating therapies. How-ever, one potential treatment that has not been well investigated in rheumatic disease is platelet-rich plasma (PRP). PRP is proposed to facilitate the healing of injured tendons and ligaments through a variety of mechanisms, including mitogenesis, angiogenesis and macrophage activation via cyto-kine release, although its exact mechanism is unclear. Result:: There has been a great deal of work in determining the exact preparation method and composition of PRP for regenerative purposes in or-thopedic surgery, sports medicine, dentistry, cardiac surgery, pediatric surgery, gynecology, urolo-gy, plastic surgery, ophthalmology, and dermatology. Despite this, there is a paucity of research on the impact of PRP on rheumatic disease Conclusion:: This study aims to summarize and evaluate the current research concerning the use of PRP in rheumatic disease.
- 3 August 2023
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 19 (4) , 400-407
Open AccessCurrent State of Platelet-rich Plasma in the Treatment of Rheumatic Disease: A Retrospective Review of the Literature
Introduction: Rheumatic diseases are a spectrum of autoimmune or inflammatory diseases that cause damage to the musculoskeletal system as well as vital organs, such as the heart, lungs, kidneys, and central nervous system. Methods: The study of rheumatic disease has made great pro-gress in the understanding and management of these conditions in the last few decades using dis-ease-modifying antirheumatic drugs and synthesized biological immunomodulating therapies. How-ever, one potential treatment that has not been well investigated in rheumatic disease is platelet-rich plasma (PRP). PRP is proposed to facilitate the healing of injured tendons and ligaments through a variety of mechanisms, including mitogenesis, angiogenesis and macrophage activation via cyto-kine release, although its exact mechanism is unclear. Result:: There has been a great deal of work in determining the exact preparation method and composition of PRP for regenerative purposes in or-thopedic surgery, sports medicine, dentistry, cardiac surgery, pediatric surgery, gynecology, urolo-gy, plastic surgery, ophthalmology, and dermatology. Despite this, there is a paucity of research on the impact of PRP on rheumatic disease Conclusion:: This study aims to summarize and evaluate the current research concerning the use of PRP in rheumatic disease.
- 16 July 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (3) , 1141-1145
Pyoderma gangrenosum associated with limited cutaneous systemic sclerosis: a rare case with literature review
Pyoderma gangrenosum (PG) is a skin disease characterized by painful ulcers that, when not appropriately treated, can lead to permanent disfigurement. Pyoderma gangrenosum has been observed in a multitude of autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease (IBD), and sarcoidosis (Feld et al. J Rheumatol. 39(1):197, 2012; Herrero et al. J Rheumatol. 36:7:1557–1558, 2009). It is rarely associated with autoimmune disorders such as systemic sclerosis. We report a case of a patient with known limited cutaneous systemic sclerosis who developed an ulcerated lesion on the 2nd digit of the left hand. The lesion was initially thought to be cellulitis and the patient underwent superficial wound debridement. Postoperatively, the patient’s lesions worsened. The patient was treated with intravenous (IV) methylprednisolone and 0.05% topical clobetasol due to high suspicion for PG with complete resolution of ulcerated lesions and minimal scarring.
- 16 July 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (3) , 1141-1145
Pyoderma gangrenosum associated with limited cutaneous systemic sclerosis: a rare case with literature review
Pyoderma gangrenosum (PG) is a skin disease characterized by painful ulcers that, when not appropriately treated, can lead to permanent disfigurement. Pyoderma gangrenosum has been observed in a multitude of autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease (IBD), and sarcoidosis (Feld et al. J Rheumatol. 39(1):197, 2012; Herrero et al. J Rheumatol. 36:7:1557–1558, 2009). It is rarely associated with autoimmune disorders such as systemic sclerosis. We report a case of a patient with known limited cutaneous systemic sclerosis who developed an ulcerated lesion on the 2nd digit of the left hand. The lesion was initially thought to be cellulitis and the patient underwent superficial wound debridement. Postoperatively, the patient’s lesions worsened. The patient was treated with intravenous (IV) methylprednisolone and 0.05% topical clobetasol due to high suspicion for PG with complete resolution of ulcerated lesions and minimal scarring.
- 18 May 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (7) , 1171-1176
Angiostrongyliasis infection masquerading as granulomatosis with polyangiitis: a case-based review
Pulmonary angiitis is a small vessel vasculitis commonly reported in granulomatosis with polyangiitis (GPA) but is rarely attributed to angiostrongyliasis. We report a case of a patient with well-controlled rheumatoid arthritis, who was treated for GPA based on lung biopsy results with glucocorticoids (GC). Upon re-review of the initial pathology, along with peripheral eosinophilia and history of recent travel, the patient was eventually diagnosed with angiostrongylus-like nematode infection. GCs were subsequently discontinued and instead, the patient was treated with anthelmintics with complete resolution of symptoms. Commonly associated with eosinophilic meningitis or abdominal angiostrongyliasis in humans, clinical pulmonary manifestations of this parasite species are rare. With parasitic infiltration of the pulmonary vessels mimicking clinical GPA, diagnosis and treatment can be difficult in these patients. We discuss the third-reported case and first-reported survivor of Angiostrongylus-induced pulmonary angiitis followed by a focused review of the literature.
- 18 May 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (7) , 1171-1176
Angiostrongyliasis infection masquerading as granulomatosis with polyangiitis: a case-based review
Pulmonary angiitis is a small vessel vasculitis commonly reported in granulomatosis with polyangiitis (GPA) but is rarely attributed to angiostrongyliasis. We report a case of a patient with well-controlled rheumatoid arthritis, who was treated for GPA based on lung biopsy results with glucocorticoids (GC). Upon re-review of the initial pathology, along with peripheral eosinophilia and history of recent travel, the patient was eventually diagnosed with angiostrongylus-like nematode infection. GCs were subsequently discontinued and instead, the patient was treated with anthelmintics with complete resolution of symptoms. Commonly associated with eosinophilic meningitis or abdominal angiostrongyliasis in humans, clinical pulmonary manifestations of this parasite species are rare. With parasitic infiltration of the pulmonary vessels mimicking clinical GPA, diagnosis and treatment can be difficult in these patients. We discuss the third-reported case and first-reported survivor of Angiostrongylus-induced pulmonary angiitis followed by a focused review of the literature.
- Open Access
- 1 February 2018
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 4 (1) , e000318
Osteochondral defects of the talus with a focus on platelet-rich plasma as a potential treatment option: a review
Objective To provide a review of osteochondral lesions of the talus, to discuss the evidence of the risks and benefits of platelet-rich plasma (PRP) as a viable treatment option, and to measure the efficacy of PRP using MRI evidence of cartilage regeneration, as well as scales that measure improvement in ‘pain’ and ‘functionality’. Eligibility criteria Studies that use PRP in either conservative or intraoperative settings to treat osteochondral defects of the talus. Results There are seven studies that compare hyaluronic acid or standard surgical options against PRP in treating osteochondral lesions of the talus. Five studies use PRP as supplemental treatment in intraoperative settings, while two studies use PRP conservatively as intra-articular injections. There were minimal adverse effects. Pain and functionality scores consistently improved in those who underwent PRP treatments over the course of 4 years. MRI showed significant but inconsistent results in chondral regeneration. Conclusion PRP may show clinical benefit in those with osteochondral lesions of the talus in terms of pain and functionality, although chondral regeneration via MRI is inconsistent. Limitations include the small sample sizes in these seven studies, as well as no standardised formula for PRP preparation. Clinical relevance To serve as an overview of the literature regarding PRP treatment for osteochondral lesions of the talus and how this modality may improve patient outcomes in pain, functionality and chondral regeneration. A case is reported to complement the subject review.
- 1 February 2018
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 4 (1) , e000318
Open AccessOsteochondral defects of the talus with a focus on platelet-rich plasma as a potential treatment option: a review
Objective To provide a review of osteochondral lesions of the talus, to discuss the evidence of the risks and benefits of platelet-rich plasma (PRP) as a viable treatment option, and to measure the efficacy of PRP using MRI evidence of cartilage regeneration, as well as scales that measure improvement in ‘pain’ and ‘functionality’. Eligibility criteria Studies that use PRP in either conservative or intraoperative settings to treat osteochondral defects of the talus. Results There are seven studies that compare hyaluronic acid or standard surgical options against PRP in treating osteochondral lesions of the talus. Five studies use PRP as supplemental treatment in intraoperative settings, while two studies use PRP conservatively as intra-articular injections. There were minimal adverse effects. Pain and functionality scores consistently improved in those who underwent PRP treatments over the course of 4 years. MRI showed significant but inconsistent results in chondral regeneration. Conclusion PRP may show clinical benefit in those with osteochondral lesions of the talus in terms of pain and functionality, although chondral regeneration via MRI is inconsistent. Limitations include the small sample sizes in these seven studies, as well as no standardised formula for PRP preparation. Clinical relevance To serve as an overview of the literature regarding PRP treatment for osteochondral lesions of the talus and how this modality may improve patient outcomes in pain, functionality and chondral regeneration. A case is reported to complement the subject review.